Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)
- Previous Close
1.160 - Open
1.160 - Bid 1.160 x --
- Ask 1.170 x --
- Day's Range
1.150 - 1.160 - 52 Week Range
1.070 - 1.400 - Volume
72,000 - Avg. Volume
225,084 - Market Cap (intraday)
1.74B - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
2.90 - EPS (TTM)
0.400 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.06 (5.43%)
- Ex-Dividend Date May 27, 2025
- 1y Target Est
--
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. Dawnrays Pharmaceutical (Holdings) Limited was founded in 1995 and is headquartered in Wan Chai, Hong Kong.
www.dawnrays.com1,183
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2348.HK
View MorePerformance Overview: 2348.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2348.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2348.HK
View MoreValuation Measures
Market Cap
1.74B
Enterprise Value
311.34M
Trailing P/E
2.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.53
Price/Book (mrq)
0.49
Enterprise Value/Revenue
0.27
Enterprise Value/EBITDA
0.39
Financial Highlights
Profitability and Income Statement
Profit Margin
53.28%
Return on Assets (ttm)
3.31%
Return on Equity (ttm)
18.20%
Revenue (ttm)
1.06B
Net Income Avi to Common (ttm)
564.94M
Diluted EPS (ttm)
0.400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.61B
Total Debt/Equity (mrq)
1.04%
Levered Free Cash Flow (ttm)
-18.43M